N Engl J Med 2014 Sep 27
Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer.
Related Questions
What is your preferred first line therapy for ROS-1 rearranged metastatic NSCLC for patients presenting with CNS metastases?
1 Answers
Mednet Member
Medical Oncology · Wexner Medical Center at The Ohio State University
The recognition of ROS1 as a distinct actionable translocation in NSCLC, and approval of crizotinib in 2016 based upon an expansion cohort of the original phase I study of crizotinib (N Engl J Med. 2014 Nov 20;371(21):1963-71) was an important step. Unfortunately, the limitations of crizotinib in AL...
What would you use as next line of treatment for a patient with ROS1+ metastatic NSCLC progressing on first line TKI?
3 Answers
Mednet Member
Medical Oncology · Wexner Medical Center at The Ohio State University
The finding that crizotinib was quite active in ROS1 altered cancers (Shaw et al., PMID 25264305 - confirmed in East Asian patients - Wu et al., PMID 29596029) obviously altered the practice of thoracic oncology, and led to the approval of crizotinib in patients with ROS1 translocations. Moreover, t...